Durham-based Altis Biosystems is offering a research award of up to $10,000 for a scientific team to use its proprietary drug-development technology in a research project.
Posted on 761
Altis Biosystems, Inc., developer of RepliGut®, a technology platform that produces a layer of human intestinal stem or differentiated cells of either the small intestine or colon, announced the appointment of Bill Thelin, Ph.D. to the role of Chief Scientific Officer. Dr. Thelin brings over 15 years of scientific experience to Altis and will coordinate research, new platform development and validation efforts.
“I am extraordinarily pleased that Bill is joining our team,” said Michael Biron, CEO of Altis. “His deep experience in developing platforms, drugs, and leveraging strategic partnerships will further strengthen our biology research engine and provide critical scientific vision to support the successful advancement of our pipeline of RepliGut